All the data on the vaccination campaign against covid-19 in the Basque Country


Society

Coronavirus

EITB AVERAGE

See here all the details about the vaccination process against covid-19: vaccination criteria, type of authorized vaccines and number of doses administered.

How many vaccines have been authorized and what are their characteristics? What are the vaccination criteria? How many doses have been administered in Álava, Bizkaia and Gipuzkoa?

Check the following graphs for all the data on the vaccination campaign against covid-19, which began on December 27, 2020.

91,2 %

Have received at least one dose

90,3 %

Complete immunization

3,1 %

They have a contraindication or have refused

VACCINES DISTRIBUTED AND ADMINISTRATED BY TRADEMARK BioNTech / Pfizer Modern / Lonza * AstraZeneca* Janssen Total
No. of vaccines received 2 647 530 526 100 444 200 101 300 3 719 130
Administered dose 2 572 241 366 238 477 887 99 078 3 515 444
% administered doses 97,2 % 69,6 % 107,6 % 97,8 % 94,5 %
1st dose administered 1 135 489 172 610 256 908 1 565 007
2nd dose administered 1 164 861 167 750 214 127 1 546 738
Single dose 108 236 25 878 6 852 99 078 240 044
Vaccine characteristics
Laboratory Vaccine type Storage Regulatory situation Second dose
Pfizer/BioNTech MRNA Freezing -80ºC EMA approved 21 days
Modern / Lonza MRNA Freezing -25ºC EMA approved 28 days
AstraZeneca/Oxford Adenovirus Refrigeration 2- 8ºC EMA approved 10-12 weeks
Johnson & Johnson/Janssen Adenovirus Refrigeration 2- 8ºC EMA approved
Novavax Nanoparticulas Refrigeration 2- 8ºC
Curevac MRNA Refrigeration 2- 8ºC
Sanofi Pasteur y GSK Recombinante baculovirus Refrigeration 2- 8ºC
Laboratory
Pfizer/BioNTech
Vaccine type MRNA
Storage Freezing -80ºC
Regulatory situation EMA approved
Second dose 21 days
Modern / Lonza
Vaccine type MRNA
Storage Freezing -25ºC
Regulatory situation EMA approved
Second dose 28 days
AstraZeneca/Oxford
Vaccine type Adenovirus
Storage Refrigeration 2- 8ºC
Regulatory situation EMA approved
Second dose 10-12 weeks
Johnson & Johnson/Janssen
Vaccine type Adenovirus
Storage Refrigeration 2- 8ºC
Regulatory situation EMA approved
Second dose Single dose
Novavax
Vaccine type Nanoparticulas
Storage Refrigeration 2- 8ºC
Regulatory situation
Second dose
Curevac
Vaccine type MRNA
Storage Refrigeration 2- 8ºC
Regulatory situation
Second dose
Sanofi Pasteur y GSK
Vaccine type Recombinante baculovirus
Storage Refrigeration 2- 8ºC
Regulatory situation
Second dose

Including the 11th doses obtained from the vials. Therefore, up to 110% of the vaccines received in recent months could be given.

VACCINES ADMINISTERED BY AGE GROUP % 1st dose % 2nd dose
100 years or more 95,8 % 94,7 %
90-99 years 93,5 % 93,5 %
80-89 years 97,3 % 97,1 %
70-79 years 96 % 96 %
60-69 years 94,6 % 94,6 %
50-59 years 94,9 % 93,6 %
40-49 years 91,5 % 90,8 %
30-39 years 84,4 % 82,6 %
20-29 years 80,7 % 78,8 %
16-19 years 89,9 % 87,3 %
12-15 years 89,5 % 87,2 %

Last update: September 20

2nd DOSE IN PEOPLE UNDER 60 YEARS OLD WITH 1st DOSE OF ASTRAZENECA 1st dose administered 2nd dose of Pfizer 2ª dose of Astrazeneca
50-59 years 22 064 10 494 10 439
40-49 years 24 832 11 058 12 371
30-39 years 18 477 7892 9431
20-29 years 15 497 6982 7508
Total 80 870 36 426 39 749
Census 3rd dose administered %
> = 90 years 31 762 20 509 64,6 %
80-89 years 120 599 57 062 47,3 %
70-79 years 207 577 20 694 10 %
1 423 074 8304 0,6 %




www.eitb.eus

See also  'Rail sale' offers more than a million half-price tickets in April and May

Related Posts

George Holan

George Holan is chief editor at Plainsmen Post and has articles published in many notable publications in the last decade.

Leave a Reply

Your email address will not be published.